| Catalog No. | HW338066 |
|---|
| Species reactivity | Human |
|---|
| Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
|---|
| Host species | Humanized |
|---|
| Isotype | IgG1-kappa |
|---|
| Expression system |
Mammalian Cells |
| Clonality |
Monoclonal |
| Target |
FLK-1, Kinase insert domain receptor, VEGFR2, Fetal liver kinase 1, CD309, Vascular endothelial growth factor receptor 2, Protein-tyrosine kinase receptor flk-1, FLK1, VEGFR-2, KDR |
| Endotoxin level |
Please contact the lab for this information. |
| Purity |
>95% purity as determined by SDS-PAGE. |
| Purification |
Protein A/G purified from cell culture supernatant. |
| Accession |
P35968 |
| Form |
Liquid |
| Storage buffer |
0.01M PBS, pH 7.4. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
|
| Stability and Storage |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
| Alternate Names | AK109, AK-109, AK1092428381-49-9 |
|---|
| Background | Alacizumab pegol is an antineoplastic agent. Chemically, it is a pegylated F(ab')2 fragment of a monoclonal antibody.
• Flk-1/KDR mediates ethanol-stimulated endothelial cell Notch signaling and angiogenic activity., PMID:25322777
• VEGFR2 and CD34 expression associated with longer survival in patients with pleural mesothelioma in the IFCT-GFPC-0701 MAPS phase 3 trial., PMID:37393757
• Vascular endothelial growth factor receptor 2, but not S100A4 or S100A6, correlates with prolonged survival in advanced urothelial carcinoma., PMID:24880461
• Glioma stem cells-derived exosomes promote the angiogenic ability of endothelial cells through miR-21/VEGF signal., PMID:28410224
|
|---|
| Note |
For research use only. Not suitable for clinical or therapeutic use. |
中文
English
